Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
TLK286.2012
NCT00047801
October 2002
September 2004
Name | Location |
---|---|
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
UCLA Medical Center | Los Angeles, California 90095-7059 |
M.D. Anderson Cancer Center | Houston, Texas 77030 |
Cancer Institute Medical Group | Los Angeles, California 90025 |